Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations

被引:33
作者
Qu, Shiqiang [1 ,2 ,3 ,4 ]
Li, Bing [1 ,2 ,3 ,4 ]
Qin, Tiejun [1 ,2 ,3 ]
Xu, Zefeng [1 ,2 ,3 ,4 ]
Pan, Lijuan [1 ,2 ,3 ]
Hu, Naibo [1 ,2 ,3 ]
Huang, Gang [5 ,6 ,7 ]
Gale, Robert Peter [8 ]
Xiao, Zhijian [1 ,2 ,3 ,4 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, MDS & MPN Ctr, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Natl Clin Res Ctr Blood Dis, Tianjin, Peoples R China
[5] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA
[6] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA
[7] Cincinnati Childrens Hosp Med Ctr, Div Canc Biol, Cincinnati, OH 45229 USA
[8] Imperial Coll London, Dept Immunol & Inflammat, Haematol Sect, London, England
关键词
DDX41; variants; genetic predisposition; myelodysplastic syndromes; demethylation therapy; BIOLOGICAL IMPLICATIONS; FAMILY;
D O I
10.1111/bjh.16668
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We screened 47 subjects with DDX41 variants among 1529 subjects with myeloid neoplasms. The most common germline variants included Splice c.935 + 4A>T, p.T360Ifs*33, p.V152G, p.S217Ifs*4, p.R311* and p.R369*. Except for the p.R369*, no other variants have been previously reported. Clinical covariates of subjects with simple DDX41 somatic variants and germline/somatic biallelic variants are similar. The two-year overall survival (OS) of subjects with DDX41 variants was 85%. Overall response rate to demethylation therapy in subjects with DDX41 variants was 69%. The response did not correlate with the presence of a germline variant.
引用
收藏
页码:1006 / 1010
页数:5
相关论文
共 14 条
  • [1] Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation
    Abou Dalle, Iman
    Kantarjian, Hagop
    Bannon, Sarah A.
    Kanagal-Shamanna, Rashmi
    Routbort, Mark
    Patel, Keyur P.
    Hu, Shimin
    Bhalla, Kapil
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (02) : 227 - 229
  • [2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [3] Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation
    Berger, G.
    van den Berg, E.
    Sikkema-Raddatz, B.
    Abbott, K. M.
    Sinke, R. J.
    Bungener, L. B.
    Mulder, A. B.
    Vellenga, E.
    [J]. LEUKEMIA, 2017, 31 (02) : 520 - 522
  • [4] Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia
    Cardoso, S. R.
    Ryan, G.
    Walne, A. J.
    Ellison, A.
    Lowe, R.
    Tummala, H.
    Rio-Machin, A.
    Collopy, L.
    Al Seraihi, A.
    Wallis, Y.
    Page, P.
    Akiki, S.
    Fitzgibbon, J.
    Vulliamy, T.
    Dokal, I.
    [J]. LEUKEMIA, 2016, 30 (10) : 2083 - 2086
  • [5] Myeloid neoplasms with germline DDX41 mutation
    Cheah, Jesse J. C.
    Hahn, Christopher N.
    Hiwase, Devendra K.
    Scott, Hamish S.
    Brown, Anna L.
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (02) : 163 - 174
  • [6] Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia
    Kadono, Moe
    Kanai, Akinori
    Nagamachi, Akiko
    Shinriki, Satoru
    Kawata, Jin
    Iwato, Koji
    Kyo, Taiichi
    Oshima, Kumi
    Yokoyama, Akihiko
    Kawamura, Takeshi
    Nagase, Reina
    Inoue, Daichi
    Kitamura, Toshio
    Inaba, Toshiya
    Ichinohe, Tatsuo
    Matsui, Hirotaka
    [J]. EXPERIMENTAL HEMATOLOGY, 2016, 44 (08) : 745 - 754
  • [7] Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies
    Lewinsohn, Maya
    Brown, Anna L.
    Weinel, Luke M.
    Phung, Connie
    Rafidi, George
    Lee, Ming K.
    Schreiber, Andreas W.
    Feng, Jinghua
    Babic, Milena
    Chong, Chan-Eng
    Lee, Young
    Yong, Agnes
    Suthers, Graeme K.
    Poplawski, Nicola
    Altree, Meryl
    Phillips, Kerry
    Jaensch, Louise
    Fine, Miriam
    D'Andrea, Richard J.
    Lewis, Ian D.
    Medeiros, Bruno C.
    Pollyea, Daniel A.
    King, Mary-Claire
    Walsh, Tom
    Keel, Sioban
    Shimamura, Akiko
    Godley, Lucy A.
    Hahn, Christopher N.
    Churpek, Jane E.
    Scott, Hamish S.
    [J]. BLOOD, 2016, 127 (08) : 1017 - 1023
  • [8] Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes
    Li, Bing
    Liu, Jinqin
    Jia, Yujiao
    Wang, Jingya
    Xu, Zefeng
    Qin, Tiejun
    Shi, Zhongxun
    Song, Zhen
    Peng, Shuailing
    Huang, Huijun
    Fang, Liwei
    Zhang, Hongli
    Pan, Lijuan
    Hu, Naibo
    Qu, Shiqiang
    Zhang, Yue
    Wu, Jian
    Liu, Na
    Ru, Kun
    Huang, Gang
    Xiao, Zhijian
    [J]. GENES CHROMOSOMES & CANCER, 2018, 57 (02) : 80 - 88
  • [9] Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia
    Li, Ruijuan
    Sobreira, Nara
    Witmer, P. Dane
    Pratz, Keith W.
    Braunstein, Evan M.
    [J]. HAEMATOLOGICA, 2016, 101 (06) : E228 - E231
  • [10] Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
    Negoro, E.
    Radivoyevitch, T.
    Polprasert, C.
    Adema, V.
    Hosono, N.
    Makishima, H.
    Przychodzen, B.
    Hirsch, C.
    Clemente, M. J.
    Nazha, A.
    Santini, V.
    McGraw, K. L.
    List, A. F.
    Sole, F.
    Sekeres, M. A.
    Maciejewski, J. P.
    [J]. LEUKEMIA, 2016, 30 (12) : 2405 - 2409